Emideltide (DSIP)
Also known as: DSIP, Delta sleep-inducing peptide
Overview
Emideltide is the International Nonproprietary Name (INN) that appears in U.S. regulatory discussions for DSIP (delta sleep-inducing peptide), a short peptide historically investigated for sleep and stress-related effects. DSIP has been marketed widely online despite limited modern clinical evidence and an unclear mechanism of action. In practice, most products are sold as ‘DSIP,’ but advisory committee agendas and legal analyses often use the INN ‘Emideltide.’ For clinicians and patients, the naming matters because a regulatory docket may list Emideltide even if the marketplace talks about DSIP. In the U.S., Emideltide/DSIP is not an FDA-approved drug. If it were ever considered for compounding eligibility under Section 503A, the FDA would still weigh whether the substance can be adequately characterized, whether there are safety concerns (including immunogenicity and impurities), and whether any evidence supports the specific uses being proposed.
Mechanism of Action
DSIP/Emideltide has been reported to affect sleep architecture and neuroendocrine signaling in some experimental settings, but a definitive receptor target and reproducible human pharmacology have not been established.
Potential Benefits
- Research-stage only; no FDA-approved indications.
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
No established dosing. Online dosing regimens are not evidence-based; discuss any use with a licensed clinician.
Routes of Administration
Not established
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
Need exact syringe measurements?
Amino Acid Sequence
Not yet characterized
Side Effects & Safety
- Human safety data are limited; potential risks include contamination/impurities from non-pharmaceutical sources and unknown long-term effects.
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy/breastfeeding (unknown safety)
Active cancer or history of hormone-sensitive malignancy (risk unknown)
Drug Interactions
- Unknown; insufficient human data
FDA Safety Information
Not FDA-approved. Compounding status is subject to FDA policy and advisory committee review; quality and sterility are key risks.
Pharmacokinetics
| Half-Life | Unknown |
|---|---|
| Storage | Store per supplier/manufacturer guidance; protect from heat and light. |
Synergistic Compounds
The following compounds have been studied alongside Emideltide (DSIP) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.